ASSIST-VLA: Assessment of Symptom-Specific Improvement in Diagnosed Vaginal Atrophy Following Laser Therapy
Recruiting
Phase 4
Interventional Study
Vaginal Atrophy
Atrophic Vaginitis
Genitourinary Syndrome of Menopause (GSM)
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 18 and older
- Sex
- Female
- Trial phase
- Phase 4
- Study type
- Interventional
- Purpose
- Supportive Care
- Participants needed
- 10 (estimated)
- Sponsor
- Stratpharma AG · Industry
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Vaginal atrophy patients receiving vaginal laser therapy will be treated with daily 7-0940® following a laser session to evaluate the safety and efficacy of the product as an adjunct treatment. Clinical outcomes will be assessed using validated investigator- and patient-reported measures, with safety and symptom progression monitored throughout the study.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Diagnosed vaginal atrophy
* Access to smartphone and tablet, laptop or computer
* Access to a valid email address
* Previously completed laser therapy session schedule
Exclusion Criteria:
* Unable to provide informed consent
* Patient unable to apply topical device
* Allergy…
Contacts
No contact information available.